Reunion Neuroscience Gains FDA Breakthrough Designation for Luvesilocin After Phase 2 PPD Trial Success

Reunion Neuroscience's luvesilocin is now on a single-trial registrational path to approval in postpartum depression, a trajectory that carries direct formulation, controlled substance, and GMP compliance implications for any manufacturer preparing to support a pivotal Phase 3 programme in 2026. The FDA's Breakthrough Therapy Designation, granted following positive Phase 2 RECONNECT data, compresses the typical development timeline and raises the stakes for early CMC alignment.

The RECONNECT trial met its primary endpoint with a statistically significant reduction in depression scores on the Hamilton-adjacent MADRS scale by Day 7, with clinically meaningful effects observed as early as Day 1 post-administration. Response and remission rates across 28-day follow-up reinforced the signal. FDA feedback confirmed that a single successful Phase 3 trial would complete the data package required for a potential NDA submission, an unusually lean regulatory package for a CNS agent in this class.

Luvesilocin is a prodrug of 4-OH-DiPT administered via subcutaneous injection, a delivery route that distinguishes it from oral or intravenous psychedelic-class compounds and introduces a discrete set of manufacturing considerations. Subcutaneous formulation development, sterility assurance, and container-closure integrity testing under 21 CFR Part 211 will need to be locked early, given the accelerated timeline. As a Schedule I-adjacent serotonergic psychedelic prodrug, controlled substance handling protocols, DEA registration requirements, and chain-of-custody documentation will also require dedicated process validation planning before Phase 3 site activation.

Full RECONNECT data will be presented in an oral session at the ASCP Annual Meeting on May 26, 2026, in Miami, FL, and in a poster session at the APA Annual Meeting on May 18, 2026, in San Francisco, CA. Both presentations are titled around RE104, the compound's development-stage identifier, and will be delivered by Chief Medical Officer Mark Pollack, M.D. Parallel Phase 2 programmes in adjustment disorder (REKINDLE) and generalised anxiety disorder (RECLAIM) remain active, broadening the eventual manufacturing scope for luvesilocin across multiple indications.

The Phase 3 initiation timeline, if met, will test how quickly CDMOs and internal manufacturing teams can qualify subcutaneous fill-finish lines and establish compliant controlled substance handling frameworks for a novel CNS prodrug operating under Breakthrough Therapy Designation pressure.

Source: Reunion Neuroscience Inc. via GlobeNewswire, May 11, 2026.